Clinical Trials Browser

INDUSTRY × cemiplimab × 30 days × Clear all

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05142189 2026-04-14

LuCa-MERIT-1

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT05208944 2026-04-14

THIO Sequenced With Cemiplimab in Advanced NSCLC

Phase 2 Recruiting

227 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT04626635 2026-04-09

COMBINE-EGFR-1

Phase 1/2 Recruiting

933 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06585410 2026-04-08

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Phase 3 Recruiting

369 enrolled

Dermatologic

Skin Neoplasms

NCT06787612 2026-04-08

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Phase 2 Recruiting

220 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03916627 2026-04-06

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Phase 2 Active not recruiting

65 enrolled

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

NCT06162572 2026-04-03

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Active not recruiting

101 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03969004 2026-03-27

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Phase 3 Active not recruiting

415 enrolled 3 FDA

Dermatologic

Cutaneous Squamous Cell Carcinoma

NCT06769698 2026-03-23

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Recruiting

120 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT03491683 2026-03-19

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Phase 1/2 Active not recruiting

52 enrolled

CNS

Glioblastoma

Clinical Trials

LIMITLESS

LuCa-MERIT-1

THIO Sequenced With Cemiplimab in Advanced NSCLC

COMBINE-EGFR-1

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)